Key result
CPVT patient develops breakthrough VF after 10 years of clinical stability.
Case Report (n=1)
Demonstrates that patients with CPVT can experience life-threatening breakthrough ventricular fibrillation even after a decade of clinical stability.
Answers are grounded in this paper and cite their sources.
Raises caution for late VF breakthroughs in stable CPVT; leaves open optimal long-term risk stratification.
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare but potentially fatal genetic arrhythmia disorder characterized by ventricular tachycardia that is primarily triggered by physical exertion or emotional stress with associated elevations in adrenergic tone. The hallmark arrhythmia is bidirectional or polymorphic ventricular tachycardia (VT), which can deteriorate into ventricular fibrillation (VF), leading to syncope or sudden cardiac death.1 CPVT is most commonly linked to mutations in the RYR2 (autosomal dominant) or CASQ2 (autosomal recessive) genes, both of which impair calcium handling in cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Jáuregui-Farfán et al. (2025) conducted a case report in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (n=1). A patient with catecholaminergic polymorphic ventricular tachycardia experienced breakthrough ventricular fibrillation after a decade of clinical stability.
Synapse has enriched 10 related papers. Consider them for comparative context: